This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| ALL | |
|---|---|
| Name | Acute lymphoblastic leukemia |
| Caption | Peripheral blood smear showing lymphoblasts |
| Field | Hematologyoncology |
| Symptoms | Fever, fatigue, bleeding, bone pain, lymphadenopathy |
| Complications | Infection, anemia, hemorrhage, central nervous system involvement |
| Onset | Rapid |
| Causes | Chromosomal translocations, genetic predisposition |
| Risks | Down syndrome, prior chemotherapy, radiation exposure |
| Diagnosis | Bone marrow biopsy, flow cytometry, cytogenetics, lumbar puncture |
| Treatment | Chemotherapy, targeted therapy, hematopoietic stem cell transplantation, radiotherapy |
| Frequency | Most common childhood cancer |
ALL
Acute lymphoblastic leukemia (commonly abbreviated as ALL) is an aggressive hematologic malignancy originating from immature lymphoid progenitors in the bone marrow and blood. It predominantly affects children but also occurs in adults and is characterized by rapid proliferation of lymphoblasts leading to marrow failure and potential extramedullary spread. Diagnosis and management rely on integrated morphologic, immunophenotypic, cytogenetic, and molecular evaluation, with outcomes varying by age, genotype, and treatment access.
ALL arises from malignant transformation of B‑cell or T‑cell precursors within the hematopoietic compartment, producing a leukemic clone that infiltrates bone marrow, peripheral blood, lymph nodes, spleen, and central nervous system. Landmark discoveries linking chromosomal translocations such as t(12;21) and t(9;22) to prognosis transformed risk stratification and therapeutic approaches used in pediatric and adult protocols developed at institutions like St. Jude Children's Research Hospital, Dana‑Farber Cancer Institute, and MD Anderson Cancer Center. Epidemiologic patterns show highest incidence in children aged 2–5 years and associations with genetic syndromes such as Down syndrome and exposure histories including therapeutic radiation following malignancies like Hodgkin lymphoma.
Patients commonly present with symptoms of bone marrow failure including pallor from anemia, petechiae and ecchymoses from thrombocytopenia, and recurrent infections due to neutropenia, with physical findings of lymphadenopathy, hepatosplenomegaly, and bone pain. Central nervous system involvement can produce headaches, cranial nerve palsies, or vomiting; testicular infiltration may be evident in males. Presentations vary across age groups and by subtype: B‑precursor ALL often presents with marrow failure and mediastinal masses are more common in T‑cell ALL, a pattern noted in case series from Children's Oncology Group and adult cohorts at Mayo Clinic.
Causation involves acquired genetic alterations such as translocations generating fusion oncogenes (eg, ETV6‑RUNX1 from t(12;21), BCR‑ABL1 from t(9;22)), copy number alterations, and mutations in genes like IKZF1 and TP53. Hereditary predisposition syndromes confer elevated risk, including Down syndrome, Li‑Fraumeni syndrome, and Bloom syndrome, while prior exposure to ionizing radiation and cytotoxic agents such as topoisomerase II inhibitors used in treatment of acute myeloid leukemia or breast cancer increase incidence. Epidemiologic studies implicate perinatal factors and infectious hypotheses linked to patterns observed by researchers at Institut Gustave Roussy and Imperial College London.
Leukemogenesis involves clonal expansion of lymphoid progenitors with impaired differentiation and increased proliferation driven by fusion proteins, activated tyrosine kinases, and altered transcriptional programs; bone marrow microenvironmental interactions facilitate survival and immune evasion. WHO and FAB classifications stratify disease by immunophenotype (B‑cell precursor versus T‑cell), cytogenetic abnormalities (eg, hyperdiploidy, hypodiploidy, KMT2A rearrangements), and molecular lesions, guiding therapy as practiced in protocols from European LeukemiaNet and the National Comprehensive Cancer Network. Minimal residual disease measurement using flow cytometry or PCR assays for rearranged immunoglobulin/T‑cell receptor genes is central to response assessment and risk assignment in trials run by groups like the Children's Oncology Group.
Diagnostic evaluation includes complete blood count, peripheral blood smear showing lymphoblasts, bone marrow aspiration and biopsy with immunophenotyping by flow cytometry to detect markers such as CD10, CD19, CD20 for B‑ALL and CD2, CD3, CD7 for T‑ALL. Cytogenetic karyotyping, fluorescence in situ hybridization, and next‑generation sequencing identify prognostic alterations including BCR‑ABL1 and ETV6‑RUNX1. Cerebrospinal fluid analysis by lumbar puncture assesses CNS involvement; testicular ultrasound is used for suspected gonadal disease. Staging and risk stratification employ systems developed by groups like the Children's Oncology Group and protocols from European Society for Medical Oncology.
Initial management begins with induction chemotherapy regimens combining agents such as vincristine, corticosteroids, anthracyclines, and asparaginase, with intensification and maintenance phases tailored by risk. Targeted therapies include tyrosine kinase inhibitors (eg, imatinib, dasatinib) for BCR‑ABL1‑positive disease and monoclonal antibodies or antibody‑drug conjugates like blinatumomab and inotuzumab‑ozogamicin for relapsed/refractory cases. Chimeric antigen receptor T‑cell therapy against CD19 has shown durable remissions in refractory pediatric and adult patients in trials at institutions such as University of Pennsylvania and Memorial Sloan Kettering Cancer Center. Allogeneic hematopoietic stem cell transplantation remains a curative option for high‑risk or relapsed disease, with conditioning and donor selection informed by registries like CIBMTR.
Prognosis is heterogeneous: children achieve long‑term cure rates exceeding 80% in contemporary protocols, while adults—especially older patients—have lower survival influenced by comorbidities and adverse cytogenetics such as hypodiploidy and KMT2A rearrangements. Minimal residual disease status after induction is a powerful prognostic indicator used across studies by groups like the Children's Oncology Group and European LeukemiaNet. Relapse, particularly with CNS or marrow involvement, portends poorer outcomes and necessitates salvage strategies including targeted agents, CAR T‑cell therapy, or transplantation; survivorship issues include secondary neoplasms and treatment‑related cardiotoxicity documented in follow‑up cohorts from centers like St. Jude Children's Research Hospital.